多重用药对老年房颤患者抗凝治疗的影响  

Effect of polypharmacy on anticoagulant therapy in elderly patients with atrial fibrillation

作　　者：谢雨欣 陈一文[2] 梁颖慧[2] Xie Yuxin;Chen Yiwen;Liang Yinghui(Department of Clinical Medicine,Grade 2018,Capital Medical University,Beijing 100730,China;Department of Geriatrics,Beijing Tongren Hospital,Capital Medical University,Beijing 100730,China)

机构地区：[1]首都医科大学,北京100730 [2]首都医科大学附属北京同仁医院老年医学科,北京100730

出　　处：《中华老年医学杂志》2023年第7期877-880,共4页Chinese Journal of Geriatrics

摘　　要：心房颤动(房颤)是老年患者最常见的心律失常之一。老年房颤患者常合并共病,多重用药现象普遍,导致药物依从性下降、出血风险和心血管事件增加,患者抗凝治疗的效果受到影响。与华法林比较,利伐沙班、阿哌沙班、达比加群等非维生素K拮抗口服抗凝剂更安全有效,推荐用于老年房颤患者的抗凝治疗。研究多重用药对老年房颤患者抗凝治疗的影响有利于制定针对性的策略,实现个体化抗凝治疗,改善老年患者预后。Atrial fibrillation(AF)is a prevalent arrhythmia in elderly patients.Such patients often have comorbidities and are subjected to polypharmacy,which may lower medication compliance and increase the risk of bleeding and cardiovascular events.These factors may also affect the efficacy of anticoagulant therapy.According to research,non-vitamin K antagonistic oral anticoagulants like Rivaroxaban,Apixaban,and Dabigatran are a safer and more effective option for anticoagulant therapy in elderly patients with atrial fibrillation compared to warfarin.Studying the impact of polypharmacy on anticoagulant therapy in elderly patients with atrial fibrillation can aid in the development of personalized treatment strategies and improve the prognosis of aged patients.

关 键 词：心房颤动 抗凝药 多重用药 

分 类 号：R541.75[医药卫生—心血管疾病]